The Women's Health Initiative conundrum

Archives of Women's Mental Health

Volumn 8, Issue 1, 2005, Pages 7-14

  Birkhaeuser, M H ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Benefits; Climacteric symptoms; Estrogen therapy; Hormone therapy; Menopause; Quality of life; Risks; WHI

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEMOGRAPHY; EARLY MENOPAUSE; ESTROGEN THERAPY; FEMALE; HEALTH STATUS; HUMAN; HYPOTHESIS; METHODOLOGY; OBESITY; PATIENT SELECTION; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

ADULT; AGE FACTORS; AGED; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; CEREBROVASCULAR ACCIDENT; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGED; PATIENT SELECTION; PROGESTERONE CONGENERS; RESEARCH DESIGN; UNITED STATES; WOMEN'S HEALTH;

EID: 21044435820     PISSN: 14341816     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00737-005-0066-z     Document Type: Review

References (33)

1. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB (1990) Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10: 1051-1057.
2. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK (1997) MPA antagonizes inhibitory effects of CEE on coronary artery atherosclerosis Arterioscler, Thromb Vasc Biol 17: 217-221.
3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women's Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 291: 1701-1712.
4. Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362: 419-427.
5. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB, for the Women's Health Initiative Investigators (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA 290: 1729-1738.
6. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Olane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. JAMA 289: 3243-3253.
7. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-1727.
8. Clarkson TB, Appt SE (2003) MPA and postmenopausal coronary artery atherosclerosis revisited. Steroids 68: 941-951.
9. Gerhard M, Walsh BW, MD, Tawakol A, Haley EA, Creager SJ, Seely EW, Ganz P, Creager MA (1998) Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 98: 1158-1163.
10. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH (1996) Postmenopausal estrogen and progestin use an the risk of cardiovascular disease. N Engl J Med 335: 453-461.
11. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs Ch, Hankinson SE, Hunter DJ, Hennekens CH, Speizer EE (1997) Postmenopausal hormone therapy and mortality. N Engl J Med 336: 1769-1775.
12. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ (2000) A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933-941.
13. Guideliness for the hormone treatment of women in the menopausal transition and beyond (2004) Position Statement by the Executive Committee of the International Menopause Society. Climacteric 7: 333-337.
14. Hays J, Ockene JK, Brunner RL, Kotchen Jm, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG, Women's Health Initiative Investigators (2003) Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348: 1839-1854.
15. Herrington DM, Reboussin DR, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D (2000) Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 343: 522-529.
16. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA, for the HERS Research Group (2002) Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the HERS Trial. JAMA 287: 591-597.
17. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Seizer RH, Liu Cr CR, Liu Ch CH, Azen SP, Estrogen in the Prevention of Atherosclerosis Trial Research Group (2001) Estrogen in the prevention of atherosclerosis: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 135: 939-953.
18. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the HERS Research Group (1998) Randomized trial for estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605-513.
19. Joakimsen O, Bønaa KH, Stensland-Bugge E, Jacobsen BK (2000) Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis. J Clin Epidemiol 53: 525-530.
20. Lobo RA (2004) Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women. Arch Intern Med 164: 482-484.
21. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, M.D., Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523-534.
22. Mikkola TS, Clarkson TB (2002) Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 15: 605-619.
23. Naftolin F, Taylor HS, Karas R (2004) Early initiation of hormone therapy and clinical cardioprotection: The Women's Health Initiative (WHI) could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 81: 1498-1501.
24. Newton KM, LaCroix AZ, Leveille SG, Rutter C, Keenan NL, Anderson LA (1997) Women's beliefs and decisions about hormone replacement therapy. J Womens Health 6(4): 459-465.
25. Register TC, Adams MR, Golden DL, Clarkson TB (1998) Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 18: 1164-1171.
26. Rossouw JE, Anderson GL, Prentice RL, et al., Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 288: 321-333.
27. Scarabin P-Y, Oger E, Plu-Bureau G, ES and THromboEmbolism Risk (ESTHER) Study Group (2003) Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362: 428-432.
28. th Workshop of the International Menopause Society. Parthenon Press, London.
29. Sherwin BB (1991) The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 72(2): 336-343.
30. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett-Connor E, Hulley SB, HERS Research Group (2001) Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen-progestin Replacement Study 8HERS). Circulation 103: 638-642.
31. Wiklund I, Karlberg J, Mattsson LA (1993) Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 168: 824-830.
32. Williams JK, Anthony MS, Honoré EK, Herrington DM, Morgan TM, Register TC, Clarkson TB (1995) Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 15: 827-836.
33. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC, Cache County Memory Study Investigators (2002) Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 288: 2123-2129.